Editing Suxamethonium chloride (section)

===Malignant hyperthermia===
{{unreferenced section|date=January 2020}}
[[Malignant hyperthermia]] (MH) from suxamethonium administration can result in a drastic and uncontrolled increase in skeletal muscle [[oxidative metabolism]]. This overwhelms the body's capacity to supply [[oxygen]], remove [[carbon dioxide]], and regulate body temperature, eventually leading to circulatory collapse and death if not treated quickly.

Susceptibility to malignant hyperthermia is often inherited as an [[autosomal dominant]] disorder, for which there are at least six [[gene|genetic loci]] of interest, the most prominent being the [[ryanodine]] receptor gene (RYR1). MH susceptibility is [[phenotypically|phenotype]] and genetically related to [[central core disease]] (CCD), an autosomal dominant disorder characterized both by MH symptoms and by [[myopathy]]. MH is usually unmasked by [[anesthesia]], or when a family member develops the symptoms. There is no simple, straightforward test to diagnose the condition. When MH develops during a procedure, treatment with [[dantrolene]] sodium is usually initiated; dantrolene and the avoidance of suxamethonium administration in susceptible people have markedly reduced the mortality from this condition.